VAERS accepts reports of adverse events and reactions that occur following vaccination. Healthcare providers, vaccine manufacturers, and the public can submit reports to the system. While very important in monitoring vaccine safety, VAERS reports alone cannot be used to determine if a vaccine caused or contributed to an adverse event or illness. The reports may contain information that is incomplete, inaccurate, coincidental, or unverifiable. In large part, reports to VAERS are voluntary, which means they are subject to biases. This creates specific limitations on how the data can be used scientifically. Data from VAERS reports should always be interpreted with these limitations in mind.
The strengths of VAERS are that it is national in scope and can quickly provide an early warning of a safety problem with a vaccine. As part of CDC and FDA’s multi-system approach to post-licensure vaccine safety monitoring, VAERS is designed to rapidly detect unusual or unexpected patterns of adverse events, also known as “safety signals.” If a safety signal is found in VAERS, further studies can be done in safety systems such as the CDC’s Vaccine Safety Datalink (VSD) or the Clinical Immunization Safety Assessment (CISA) project. These systems do not have the same scientific limitations as VAERS, and can better assess health risks and possible connections between adverse events and a vaccine.
Key considerations and limitations of VAERS data:
VAERS data available to the public include only the initial report data to VAERS. Updated data which contains data from medical records and corrections reported during follow up are used by the government for analysis. However, for numerous reasons including data consistency, these amended data are not available to the public.
Patient presented to the emergency room with acute chest pain in the sternal area and a troponin of 1.1. EKG showed early repolarization, not concerning for ACS. Her pain was classic for pericarditis in that it was worse when leaning back, nonexertional, and not accompanied by diaphoresis or nausea. She was treated for presumed pericarditis with ibuprofen and colchicine. Her troponin peaked at 4.6 and then downtrended. Her chest pain resolved. She was discharged with presumed pericarditis.
Open in Wayback Machine
(If this is a foreign report without a description you will be able to read the description in the Wayback Machine on Medalerts if the report became public for the first time before November 18, 2022.)
|COVID19 (COVID19 (MODERNA))||2||COVID19||MODERNA||Unknown||Unknown|
|LAB_DATA:||Troponin: 5/23 0900 1.17 5/23 1230 4.66 5/23 2200 3.49 5/24 0600 2.65 Chest x-ray: normal, no sign of pneumothorax|
|OTHER_MEDS:||Amphetamine- dextroamphetamine ER 25mg qam Fluoxetine 40mg qpm Levonorgestrel-ethinyl estradiol 0.15-0.03 mg qpm|
|HISTORY:||Depression ADHD SVT, ablated in 2016, asymptomatic since|
Questions? Comments? Bugs?
Due to the high volume of inquiries, please be patient with response times.
AND PLEASE read the FAQ first.